Baird Reiterates an 'Outperform' on NewLink Genetics (NLNK); Clinical Programs All On Track

Baird reiterates an 'Outperform' on NewLink Genetics (NASDAQ: NLNK) price target of $10.00.

Analyst, Christopher J. Raymond, said, "While we acknowledge that the risk/reward equation has shifted somewhat in light of NLNK's +29% move YTD (NBI +18%), with timelines for all key clinical events on track - and sufficient capital to get there - we continue to see reason to own the stock here. We continue to see fair value in the $10 range, all things equal."

Raymond also notes that NewLink has approximately $42 million in cash and should have money through 2013 (with an expected five million dollar cash burn rate per qtr)

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $9.13 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)